Comparative Pharmacology
Head-to-head clinical analysis: PROTONIX IV versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROTONIX IV versus ZEGERID OTC.
PROTONIX IV vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Renal (80% as metabolites) and fecal (20%)
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor